Cargando…
The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target
Survival rate for Chondrosarcoma (CHS) is at a standstill, more effective treatments are urgently needed. Consequently, a better understanding of CHS biology and its immune environment is crucial to identify new prognostic factors and therapeutic targets. Here, we exhaustively describe the immune la...
Autores principales: | Iseulys, Richert, Anne, Gomez-Brouchet, Corinne, Bouvier, Gonzague, Du Bouexic De Pinieux, Marie, Karanian, Jean-Yves, Blay, Aurélie, Dutour |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961717/ https://www.ncbi.nlm.nih.gov/pubmed/31956474 http://dx.doi.org/10.1016/j.jbo.2019.100271 |
Ejemplares similares
-
Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression
por: Nicolle, Rémy, et al.
Publicado: (2019) -
A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages
por: Richert, Iseulys, et al.
Publicado: (2023) -
The molecular pathogenesis of dedifferentiated chondrosarcoma
por: Sakamoto, Akio
Publicado: (2014) -
Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018) -
TCF-1 participates in the occurrence of dedifferentiated chondrosarcoma
por: Xu, Xiaolong, et al.
Publicado: (2016)